Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute.

Zeidner JF, Karp JE, Blackford AL, Foster MC, Dees EC, Smith G, Ivy SP, Harris P.

J Natl Cancer Inst. 2015 Nov 9;108(3). doi: 10.1093/jnci/djv335. Print 2016 Mar.

2.

Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California.

Ho G, Wun T, Muffly L, Li Q, Brunson A, Rosenberg AS, Jonas BA, Keegan THM.

Cancer. 2018 May 1;124(9):1938-1945. doi: 10.1002/cncr.31296. Epub 2018 Feb 16.

3.

Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patients.

Østgård LS, Nørgaard M, Sengeløv H, Medeiros BC, Kjeldsen L, Overgaard UM, Severinsen MT, Marcher CW, Jensen MK, Nørgaard JM.

Oncotarget. 2016 Nov 1;7(44):72044-72056. doi: 10.18632/oncotarget.12495.

4.

Statewide geographic variation in outcomes for adults with acute myeloid leukemia in North Carolina.

Freeman AT, Meyer AM, Smitherman AB, Zhou L, Basch EM, Shea TC, Wood WA.

Cancer. 2016 Oct;122(19):3041-50. doi: 10.1002/cncr.30139. Epub 2016 Jun 28.

5.

Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis.

Percival ME, Tao L, Medeiros BC, Clarke CA.

Cancer. 2015 Jun 15;121(12):2004-12. doi: 10.1002/cncr.29319. Epub 2015 Mar 4.

6.

Induction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States.

Kavcic M, Fisher BT, Li Y, Seif AE, Torp K, Walker DM, Huang YS, Lee GE, Tasian SK, Vujkovic M, Bagatell R, Aplenc R.

Cancer. 2013 May 15;119(10):1916-23. doi: 10.1002/cncr.27957. Epub 2013 Feb 21.

7.

Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials.

Bando H, Rubinstein L, Harris P, Yoshino T, Doi T, Ohtsu A, Welch J, Takebe N.

Gastric Cancer. 2017 May;20(3):481-488. doi: 10.1007/s10120-016-0629-x. Epub 2016 Aug 10.

PMID:
27510411
8.

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.

Pleyer L, Döhner H, Dombret H, Seymour JF, Schuh AC, Beach CL, Swern AS, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, Thaler J, Halter B, Machherndl Spandl S, Zebisch A, Pichler A, Pfeilstöcker M, Autzinger EM, Lang A, Geissler K, Voskova D, Sperr WR, Hojas S, Rogulj IM, Andel J, Greil R.

Int J Mol Sci. 2017 Feb 15;18(2). pii: E415. doi: 10.3390/ijms18020415.

9.

Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.

Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T.

J Clin Oncol. 2004 Nov 1;22(21):4384-93.

PMID:
15514380
10.

Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials.

Lynce F, Blackburn MJ, Cai L, Wang H, Rubinstein L, Harris P, Isaacs C, Pohlmann PR.

Breast Cancer Res Treat. 2018 Feb;168(1):35-41. doi: 10.1007/s10549-017-4563-3. Epub 2017 Nov 8.

11.

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R.

Clin Cancer Res. 2001 Jun;7(6):1490-6. Erratum in: Clin Cancer Res 2002 Jan;8(1):300.

12.

Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome.

Badar T, Shetty A, Bueso-Ramos C, Cortes J, Konopleva M, Borthakur G, Pierce S, Huang X, Chen HC, Kadia T, Daver N, Dinardo C, O'Brien S, Garcia-Manero G, Kantarjian H, Ravandi F.

Am J Hematol. 2015 Sep;90(9):769-73. doi: 10.1002/ajh.24074. Epub 2015 Jul 27.

13.

Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.

Meyers J, Yu Y, Kaye JA, Davis KL.

Appl Health Econ Health Policy. 2013 Jun;11(3):275-86. doi: 10.1007/s40258-013-0032-2.

PMID:
23677706
14.

Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.

Badar T, Kantarjian HM, Nogueras-Gonzalez GM, Borthakur G, Garcia Manero G, Andreeff M, Konopleva M, Kadia TM, Daver N, Wierda WG, Luthra R, Patel K, Oran B, Champlin R, Ravandi F, Cortes JE.

Am J Hematol. 2015 Nov;90(11):1065-70. doi: 10.1002/ajh.24140. Epub 2015 Sep 10.

15.

Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades.

Thein MS, Ershler WB, Jemal A, Yates JW, Baer MR.

Cancer. 2013 Aug 1;119(15):2720-7. doi: 10.1002/cncr.28129. Epub 2013 Apr 30.

16.

European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.

Burnett AK, Russell NH, Kell J, Dennis M, Milligan D, Paolini S, Yin J, Culligan D, Johnston P, Murphy J, McMullin MF, Hunter A, Das-Gupta E, Clark R, Carr R, Hills RK.

J Clin Oncol. 2010 May 10;28(14):2389-95. doi: 10.1200/JCO.2009.26.4242. Epub 2010 Apr 12.

PMID:
20385984
17.

Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.

Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F, Henze G, Jürgens H, Kabisch H, Havers W, Reiter A, Kluba U, Niggli F, Gadner H.

J Clin Oncol. 2001 May 15;19(10):2705-13.

PMID:
11352963
18.

Targeting acute myeloid leukemia with TP53-independent vosaroxin.

Benton CB, Ravandi F.

Future Oncol. 2017 Jan;13(2):125-133. Epub 2016 Sep 12. Review.

19.

[Treatment conditioning variables in elderly patients with acute myeloid leukemia. An institutional experience].

Giménez Conca AD, Arbelbide JA, Schutz N, Otero V, Fantl D, Ferreyro B.

Medicina (B Aires). 2016;76(2):81-8. Spanish.

20.

CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?

Brunetti C, Anelli L, Zagaria A, Specchia G, Albano F.

Expert Rev Hematol. 2017 Oct;10(10):853-862. doi: 10.1080/17474086.2017.1369400. Epub 2017 Aug 24. Review.

PMID:
28814164

Supplemental Content

Support Center